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Mutations in BRCA1 and BRCA2 genes predispose to breast and ovarian cancer (BC/OC) with a high lifetime risk, whereas
mutations in PALB2, CHEK2, ATM, FANCM, RAD51C and RAD51D genes cause a moderately elevated risk. In the Finnish
population, recurrent mutations have been identiﬁed in all of these genes, the latest being CHEK2 c.319+2T>A and c.444+1G>A.
By genotyping 3,156 cases and 2,089 controls, we estimated the frequencies of CHEK2 c.319+2T>A and c.444+1G>A in Finnish
BC patients. CHEK2 c.319+2T>A was detected in 0.7% of the patients, and it was associated with a high risk of BC in the
unselected patient group (OR = 5.40 [95% CI 1.58–18.45], p = 0.007) and similarly in the familial patient group. CHEK2 c.444
+1G>A was identiﬁed in 0.1% of all patients. Additionally, we evaluated the combined prevalence of recurrent moderate-risk
gene mutations in 2,487 BC patients, 556 OC patients and 261 BRCA1/2 carriers from 109 families. The overall frequency of the
mutations was 13.3% in 1,141 BRCA1/2-negative familial BC patients, 7.5% in 1,727 unselected BC patients and 7.2% in
556 unselected OC patients. At least one moderate-risk gene mutation was found in 12.5% of BRCA1 families and 7.1% of BRCA1
index patients, as well as in 17.0% of BRCA2 families and 11.3% of BRCA2 index patients, and the mutations were associated
with an additional risk in the BRCA1/2 index patients (OR = 2.63 [1.15–5.48], p = 0.011). These results support gene panel
testing of even multiple members of BC families where several mutations may segregate in different individuals.
Introduction
Breast cancer (BC) is the most common cancer in women
worldwide.1 One of the most signiﬁcant risk factors for BC is a
family history of the disease so that the risk increases along with
the number of affected ﬁrst-degree relatives.2 The major high-
risk genes predisposing to BC and ovarian cancer (OC) are
BRCA1 and BRCA2, with estimated cumulative risks of 72 and
69% for BC and 44 and 17% for OC, respectively, by the age of
80 years.3 In Finland, BRCA1/2 mutations have been detected in
21% of BC families.4 Recurrent BRCA1/2 founder mutations
have been found in 1.8% of unselected BC patients,5 in 26% of
OC families,6 and in 5.6% of unselected OC patients.7
Several genes with a moderate effect on BC or OC risk have
been identiﬁed in recent years. Mutations in PALB2 may cause a
BC risk comparable to BRCA2,8 whereas mutations in CHEK2,
ATM and FANCM have been associated with a two- to threefold
increased risk of BC compared to the general population,
FANCM particularly with the risk of a triple-negative BC
subtype.9–15 RAD51C and RAD51D have been identiﬁed primar-
ily as OC susceptibility genes, but have recently been linked also
to triple-negative BC.16–19 In addition, genome-wide association
studies have reported numerous common risk-modifying
alleles.20
In the Finnish population, the history of geographic isola-
tion and genetic bottlenecks has led to reduced variation and
enrichment of deleterious alleles.21 Consequently, just a few
recurrent mutations cover the majority of all pathogenic
mutations found in BC and OC susceptibility genes in
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Finland. PALB2 c.1592delT has been observed with a
0.7–0.9% frequency among unselected BC patients and a
2.0–2.7% frequency among familial patients in studies from
different regions in Finland.22,23 CHEK2 c.1100delC has been
found in 2.0% of unselected and in 5.5% of familial BC
patients.24 Three FANCM nonsense mutations, c.5101C>T,
c.5791C>T and c.4025_4026delCT, were recently discovered
in Finnish BC series.14,15 Of these, c.5101C>T is the most
common with a frequency of 2.8% in unselected patients,
3.1% in BC families and 5.6% in patients with triple-negative
BC.14 Two recurrent ATM mutations originally identiﬁed in
Ataxia-telangiectasia families have been detected also in BC
patients: c.6908dupA (previously marked as 6903insA) in
0.4% of unselected and in 0.6% of familial patients, and a
pathogenic missense c.7570G>C in 0.2% of both unselected
and familial patients.25,26 Finally, two mutations in RAD51C,
c.93delG and c.837+1G>A, and one in RAD51D, c.576+1G>A,
were each observed in about 0.5% of unselected OC
patients.27,28 Besides these, a likely pathogenic RAD51C ex1–7
duplication was recently identiﬁed in 0.4% of unselected OC
patients.29
Two CHEK2 splicing mutations, an Eastern European foun-
der mutation c.444+1G>A (alternatively IVS2+1G>A) and a
novel c.319+2T>A, were recently discovered in Finnish BC
patients.29,30 Here, we estimate the frequencies of CHEK2 c.444
+1G>A and c.319+2T>A among Finnish BC and OC patients
and evaluate the BC risk associated with c.319+2T>A. We report
the frequencies of ATM c.6908dupA and c.7570G>C in a large
series of BC and OC patients from Southern Finland. Further-
more, we deﬁne the overall prevalence of known recurrent
mutations in PALB2, CHEK2, FANCM, ATM, RAD51C and
RAD51D genes in Finnish BC and OC patients and study the
cooccurrence of these mutations in BC patients and families,
including families carrying BRCA1 or BRCA2mutations.
Materials and Methods
Patients
The patient series consisted of 3,156 female BC patients from
the Helsinki and Tampere University Hospital regions in South-
ern Finland, as well as of 556 OC patients and 261 BRCA1/2
carriers from Helsinki. The patient series are described in detail
below. The study was carried out with informed consent
obtained from the patients and with approval by the Ethics
committees of the Helsinki University Hospital and the
Tampere University Hospital.
Helsinki and Tampere BC series
The unselected Helsinki BC series, unselected for age and family
history, was collected prospectively at the Helsinki University
Hospital Department of Oncology in 1997–1998 and 20005,31 and
Department of Surgery in 2001–2004.32 The series consisted of
884 and 986 consecutive, newly diagnosed BC patients (79 and
87% of all new cases during the collection periods, respectively).
Of these, 1,727 patients with invasive disease were included in the
analysis. The familial Helsinki BC series consisted of 1,141 index
patients, including 381 familial cases collected among the unse-
lected series and 760 additional familial patients collected at the
Departments of Oncology and Clinical Genetics until 2015 as
previously described.24,32,33 Six hundred and nine families had
at least three ﬁrst- or second-degree relatives with BC or
OC and 532 families had two affected ﬁrst-degree relatives.
BRCA1/2-positive patients had been excluded from the familial
series. In total, 2,487 female BC patients from the Helsinki region
were included in the study (Supporting Information Fig. S1).
The unselected Tampere BC series was collected at the Tam-
pere University Hospital as previously described.5,32 The series
consisted of 408 consecutive, newly diagnosed patients collected
in 1997–1999 (75% of all new cases during the collection period),
with additional 336 incident patients collected in 1996–2004. Of
these, 669 female patients with invasive tumor were included in
the study (Supporting Information Fig. S1). Two hundred and
thirty-four of the patients had a positive family history with at
least one ﬁrst- or second-degree relative diagnosed with BC or
OC. For the Helsinki and Tampere BC series, genomic DNA was
isolated from peripheral blood samples.
OC series
The unselected Helsinki OC series was collected at the Helsinki
University Hospital Department of Obstetrics and Gynecology.
Two hundred and thirty-three patients with invasive disease
were collected retrospectively during routine follow-up visits to
the clinic in 1998 as previously described.7 Additional patients
were collected prospectively in 1998–2006. Altogether 556 cases
were included in the series. For 433 patients genomic DNA was
What’s new?
In the Finnish population, a small number of recurrent mutations account for the majority of deleterious variations in breast
and ovarian cancer susceptibility genes. The authors investigated 12 recurrent moderate-risk mutations in Finnish breast and
ovarian cancer patients. These mutations were found with similar frequency in unselected patients and BRCA1/2-positive
familial index patients, twice as often as in population controls. In addition, a novel association was identiﬁed between breast
cancer risk and CHEK2 variant c.319+2T>A. The ﬁndings highlight the relevance of gene panel testing for breast and ovarian
cancer risk assessment and its potential use for assessing breast cancer families with members who may carry different
mutations.
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isolated from blood and for 123 patients the DNA sample was
extracted from tumor tissue.
BRCA1/2 family series
The BRCA1/2-positive series consisted of 126 BRCA1 mutation
carriers (including four males) from 56 families and 135 BRCA2
mutation carriers (including 13 males) from 53 families. In
30 BRCA1 and 31 BRCA2 families, only the index patient was
genotyped. All index patients had either BC or OC (including
one male with BC) or both cancers. The index patients were ini-
tially identiﬁed from the familial or unselected Helsinki BC
series as previously described,4,5 or in diagnostic testing at the
Helsinki University Hospital Department of Clinical Genetics.
The BRCA1/2 mutations of the families are listed in the
Supporting Information Table S1. Of the BRCA1 carriers,
21 individuals were affected with both BC and OC, 60 with BC,
13 with OC, 6 with other cancer and 26 individuals were
healthy. Of the BRCA2 carriers, 10 had BC and OC, 70 had BC,
8 had OC, 18 had other cancer and 29 were healthy. Twenty-
four BRCA1/2 carriers belonged also to the Helsinki unselected
BC series and nine to the unselected OC series. For all patients,
genomic DNA was extracted from peripheral blood.
Population controls
The geographically matched population controls consisted of 1,273
healthy female blood donors from Helsinki and 816 from Tampere
regions. The Helsinki controls were collected in 2002–2003.
Genotyping
PALB2 c.1592delT, CHEK2 c.1100delC, FANCM c.5101C>T and
c.5791C>T, RAD51C c.93delG and c.837+1G>A and RAD51D
c.576+1G>A had been previously genotyped in the majority of
the samples from the Helsinki region.14,15,23,27,28,34 FANCM
c.4025_4026delCT had been genotyped in one-third of the Hel-
sinki BC cases.15 Additional cases and controls were genotyped
with TaqMan real-time PCR or with Sanger sequencing to obtain
comparable sample counts for all mutations (Supporting Infor-
mation Table S2). All study subjects from Helsinki and Tampere
were genotyped for ATM c.6908dupA and c.7570G>C with
TaqMan real-time PCR or with Sanger sequencing, for CHEK2
c.319+2T>A with Sequenom MassARRAY or with Sanger
sequencing and for CHEK2 c.444+1G>A with Sanger sequencing
(see Supporting Information Methods and Supporting Informa-
tion Table S3 for details).
Statistical analyses
The statistical analyses were performed using R (version 3.4.4)
environment for statistical computing (https://www.r-project.
org). Associations were tested with Fisher’s exact test.
Combined analysis of the Helsinki and Tampere BC series was
performed with region-stratiﬁed logistic regression. All p values
are two-sided. Further details are provided in Supporting Infor-
mation Methods.
Results
Frequencies of CHEK2 c.319+2T>A and c.444+1G>A
CHEK2 c.319+2T>A was identiﬁed in 13/1725 (0.8%) unselected
BC patients and in 11/1138 (1.0%) familial cases from the Hel-
sinki region in comparison to 1/1271 (0.1%) population controls
(Table 1). In the study subjects from the Tampere region, c.319
+2T>A was observed in 5/653 (0.8%) unselected BC patients and
in 2/806 (0.2%) population controls. In the region-stratiﬁed anal-
ysis combining the Helsinki and Tampere BC series, c.319+2T>A
was signiﬁcantly associated with increased risk of BC in the unse-
lected patient group (odds ratio (OR) = 5.40 [95% conﬁdence
interval (CI) 1.58–18.45], p = 0.007) and in the familial patient
group (OR = 6.04 [1.65–22.10], p = 0.007; Table 2). Of the muta-
tion carriers with available histological data, 19/22 (86.4%) had
estrogen receptor (ER)-positive BC. The average diagnosis age
was 54.3 years (range 33–81) for CHEK2 c.319+2T>A carriers
and 56.5 years (range 21–95) for all BC patients in the combined
dataset. In the Helsinki series, 3/18 (16.7%) carriers had bilateral
BC and two carriers had breast and other cancer (cervical cancer
or basalioma).
Three BC patients (3/3147, 0.1%), but none of the controls,
were found to carry germline CHEK2 c.444+1G>A (Table 1).
The carriers were diagnosed with BC at the ages of 40, 65 and
79 years. One of the patients had bilateral BC, while another
patient had both BC and OC. No CHEK2 c.319+2T>A or
c.444+1G>A carriers were detected in the unselected OC
series.
Frequencies of ATM c.6908dupA and c.7570G>C
ATM c.6908dupA was identiﬁed in two BC patients from the
Helsinki region, both being familial index cases (2/1140,
0.2%), and in 2/1271 (0.2%) controls (Table 1). However, the
two mutation-positive controls were young at the time of
entering the study (ages 19 and 27). In the Tampere series,
5/666 (0.8%) unselected BC patients, but none of the 812 con-
trols, carried the c.6908dupA mutation. The average age of
BC diagnosis was 53.7 years (range 30–81) among the carriers.
One of the carriers was later diagnosed with bladder cancer.
In the Helsinki BC series, ATM c.7570G>C was identiﬁed in
2/1727 (0.1%) unselected patients and in 3/1141 (0.3%) familial
patients, but in none of the controls (Table 1). In the Tampere
BC series, c.7570G>C was not identiﬁed among the patients, but
it was detected in one out of 815 (0.1%) population controls. The
average age of BC diagnosis among the c.7570G>C carriers was
50.3 years (range 28–61). One of the carriers had bilateral BC, one
had breast and thyroid cancer and one had BC and basalioma.
In the per-gene analysis of the Helsinki and Tampere BC
series, combining ATM c.6908dupA and c.7570G>C, the fre-
quency of the mutations was two- to threefold higher in the unse-
lected group (OR = 2.63 [0.69–10.01], p = 0.156) and in the
familial group (OR = 2.97 [0.71–12.37], p = 0.136; Table 2) than
in the population controls. Ten out of 12 (83.3%) carriers had
ER-positive tumors. In the unselected OC series, the c.6908dupA
mutation was detected in 2/549 (0.4%) patients (OR = 2.32
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[0.17–32.07], p = 0.589, compared to the Helsinki population con-
trols). No c.7570G>C carriers were identiﬁed among the unse-
lected OC cases.
Overall frequencies of the moderate-risk mutations in the
patients
The combined mutation frequency in the moderate-penetrance
genes was determined in the Helsinki BC and OC series. At least
one of the studied mutations in PALB2, CHEK2, ATM, FANCM,
RAD51C or RAD51D genes was detected in 243/2487 (9.8%) BC
patients (Table 3). In the unselected BC series, at least one muta-
tion was present in 129/1727 (7.5%) patients, whereas in the
familial BC series in 152/1141 (13.3%) patients. The most
common mutations among the familial index patients were
CHEK2 c.1100delC detected in 67/1141 (5.9%) cases, FANCM
c.5101C>T in 36/1141 (3.2%) cases and PALB2 c.1592delT in
27/1141 (2.4%) cases.
In the unselected OC series, at least one studied mutation
was detected in 40/556 (7.2%) patients. When only germline
DNA samples were included, at least one mutation was found
in 29/433 (6.7%) patients. FANCM was the most commonly
mutated gene among the OC patients with 13 patients carry-
ing the c.5101C>T and four carrying the c.5791C>T mutation
(total 17/556, 3.1%). Mutations in the established OC genes
RAD51C and RAD51D were identiﬁed in total in 9/556 (1.6%)
unselected OC patients.
Table 1. Frequencies of the CHEK2 and ATM mutations in the Helsinki and Tampere breast cancer series
Helsinki1 Tampere2
Mutation Study cohort Carriers/total % Carriers/total %
CHEK2 c.319+2T>A, rs587782401 Controls 1/1271 0.1 2/806 0.2
All BC 18/2484 0.7 5/653 0.8
Familial BC 11/1138 1.0 1/227 0.4
Unselected BC 13/1725 0.8 5/653 0.8
ER+ 16/1882 0.9 3/499 0.6
ER− 2/451 0.4 1/122 0.8
CHEK2 c.444+1G>A, rs121908698 Controls 0/1272 0 0/786 0
All BC 2/2485 0.1 1/662 0.2
Familial BC 1/1140 0.1 0/230 0
Unselected BC 1/1725 0.1 1/662 0.2
ER+ 1/1881 0.1 0/507 0
ER− 0/452 0 1/123 0.8
ATM c.6908dupA,
p.Glu2304GlyfsTer69, rs773570504
Controls 2/1271 0.2 0/812 0
All BC 2/2486 0.1 5/666 0.8
Familial BC 2/1140 0.2 1/232 0.4
Unselected BC 1/1726 0.1 5/666 0.8
ER+ 2/1882 0.1 4/510 0.8
ER− 0/452 0 1/124 0.8
ATM c.7570G>C,
p.Ala2524Pro, rs769142993
Controls 0/1272 0 1/815 0.1
All BC 5/2487 0.2 0/669 0
Familial BC 3/1141 0.3 0/234 0
Unselected BC 2/1727 0.1 0/669 0
ER+ 4/1883 0.2 0/513 0
ER− 1/452 0.2 0/124 0
ATM c.6908dupA and
ATM c.7570G>C combined
Controls 2/1271 0.2 1/811 0.1
All BC 7/2486 0.3 5/666 0.8
Familial BC 5/1140 0.4 1/232 0.4
Unselected BC 3/1726 0.2 5/666 0.8
ER+ 6/1882 0.3 4/510 0.8
ER− 1/452 0.2 1/124 0.8
1The cohorts are overlapping with 381 individuals included both in the familial and in the unselected patient group in the Helsinki breast cancer series.
2The Tampere unselected patient group includes the familial patient group.
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Of the population controls, 47/1273 (3.7%) carried at least
one moderate-risk mutation.
Double heterozygosity for mutations in the moderate-
penetrance genes
In the Helsinki BC series, 11 double heterozygotes were identi-
ﬁed for the studied PALB2, CHEK2, ATM or FANCM muta-
tions among all 2,487 patients, so that 7/1141 (0.6%) familial
and 7/1727 (0.4%) unselected patients carried mutations in
more than one gene. Three out of the 11 double heterozygotes
were included both in the familial and in the unselected series.
Of the mutation-positive patients in the series, 4.6% familial
and 5.4% unselected cases carried more than one mutation. All
but one identiﬁed double heterozygotes carried either CHEK2
c.1100delC or FANCM c.5101C>T, or both of the two muta-
tions (Supporting Information Table S4). Two of the double
heterozygotes had bilateral BC, and one had breast and bladder
cancer. None of the double heterozygotes in the BC series had
RAD51C or RAD51D mutations or were affected with
OC. However, one double heterozygote for ATM c.6908dupA
and FANCM c.5101C>T was identiﬁed among the unselected
OC patients (1/556, 0.2%). One healthy control, enrolled at the
age of 37 years, was identiﬁed as a heterozygote for PALB2
c.1592delT and FANCM c.5101C>T out of 1,273 (0.1%) popu-
lation controls.
The expected number of double heterozygotes based on the
mutation frequencies in the unselected series of BC cases was 4.4,
less than the observed seven. In the population controls, the
expected number of double heterozygotes was 0.7, when one was
observed. We saw a statistically signiﬁcant difference between the
frequency of the double heterozygotes in the 7/1141 familial BC
patients (OR = 7.85 [1.01–353.57], p = 0.030), but not in the
7/1727 unselected BC patients (OR = 5.17 [0.66–233.26],
p = 0.149), when compared to the 1/1273 population controls.
Moderate-risk gene mutations in BRCA1/2 families
We tested a total of 261 BRCA1 and BRCA2 carriers from
109 families for the recurrent mutations in the moderate-
penetrance genes. Four of the 56 (7.1%) BRCA1 index patients
and 6/53 (11.3%) BRCA2 index patients had at least one of the
tested PALB2, CHEK2, ATM, FANCM or RAD51C mutations
(Table 4). Two index patients carried three mutations: one OC
patient had BRCA1 c.3485delA, ATM c.6908dupA and RAD51C
c.93delG, and one BC patient had BRCA2 c.7480C>T, CHEK2
c.1100delC and FANCM c.5101C>T. However, when consider-
ing all genotyped BRCA1/2 carriers, including additional family
members from 48 of the 109 families, at least one moderate-risk
mutation was detected in 7/56 (12.5%) BRCA1 families and in
9/53 (17.0%) BRCA2 families. More than one carrier of a
moderate-risk mutation was detected in four families: two
BRCA1 families carrying ATM c.6908dupA, one BRCA2 family
with CHEK2 c.1100delC and one BRCA2 family with FANCM
c.5101C>T.
The frequency of the moderate-penetrance gene mutations
in BRCA1/2 index patients was comparable to the frequency in
the unselected BC patients, and signiﬁcantly different from the
Table 2. Combined analysis of the CHEK2 and ATM mutations in the Helsinki and Tampere breast cancer series
Mutation Study cohort OR 95% CI p-value
CHEK2 c.319+2T>A, rs587782401 All BC 5.32 1.58–17.97 0.007
Familial BC 6.04 1.65–22.10 0.007
Unselected BC 5.40 1.58–18.45 0.007
ER+ 5.52 1.61–18.93 0.007
ER− 4.34 0.84–22.38 0.080
ATM c.6908dupA,
p.Glu2304GlyfsTer69, rs773570504
All BC 3.06 0.62–15.11 0.169
Familial BC 2.12 0.34–13.36 0.422
Unselected BC 3.08 0.62–15.42 0.171
ER+ 3.27 0.64–16.65 0.154
ER− 1.81 0.16–20.79 0.633
ATM c.7570G>C, p.Ala2524Pro, rs769142993 All BC 3.07 0.35–26.84 0.311
Familial BC 4.71 0.46–48.39 0.192
Unselected BC 1.76 0.16–19.71 0.647
ER+ 3.32 0.36–30.56 0.289
ER− 4.31 0.25–73.49 0.313
ATM c.6908dupA and ATM c.7570G>C combined All BC 3.07 0.85–11.09 0.088
Familial BC 2.97 0.71–12.37 0.136
Unselected BC 2.63 0.69–10.01 0.156
ER+ 3.29 0.88–12.23 0.076
ER− 2.58 0.42–16.05 0.309
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frequency in the population controls (OR = 2.63 [1.15–5.48],
p = 0.011). Overall, our data comply with the multiplicative
risk model, which suggests that the risk effects associated
with single mutations combine multiplicatively and that the
second mutation confers additional increase in risk, which is
comparable in magnitude to its nominal risk effect (Table 5).
The tumor characteristics of all double heterozygotes with
BC or OC are presented in the Supporting Information
Table S4.
Discussion
In our study, we evaluated the overall prevalence of 12 recur-
rent moderate-risk mutations in Finnish BC and OC patients.
These mutations in PALB2, CHEK2, ATM, FANCM, RAD51C
and RAD51D genes were observed in 13.3% of the BRCA1/2-
negative familial BC patients, in 7.5% of the unselected BC
patients and in 7.2% of the unselected OC patients. The stud-
ied mutations are likely to cover the vast majority of all patho-
genic mutations in these genes in the Finnish population. We
have not detected any other pathogenic mutations in PALB2,
CHEK2, ATM, FANCM, RAD51C or RAD51D among 231 BC
or OC patients from 174 families in whole-genome, whole-
exome or gene-panel sequencing14,29 (unpublished data). To
the best of our knowledge, no other moderate-risk mutations
in these genes have been reported in Finnish BC or OC
patients. Furthermore, no other loss-of-function mutations
have been identiﬁed among over 12,000 Finns included in the
GnomAD database in RAD51D gene and only a few very rare
or single variants in the other genes.35 Even if some rare
mutations may remain undetected, our results represent the
minimum overall frequencies of the moderate-risk mutations
in these genes in the BC and OC patients in Finland.
Recently, Couch et al.36 reported the overall frequency of
pathogenic variants in 21 BC or OC risk and candidate genes
to be 10.2% in a Caucasian BC cohort enriched with familial
cases. However, when excluding BRCA1/2 carriers, the com-
bined frequency was 6.2%.36 We observed the 12 recurrent
moderate-risk mutations over twice as often in the BRCA1/2-
negative familial index cases and the frequency of the muta-
tions was 7.5% even in the unselected series of BC patients.
Thus, in a population with a history of isolation, the effect of
just a dozen founder mutations could be more substantial than
the effect of multiple rare variants in many genes in outbred
populations. Hence, the national guidelines of genetic counsel-
ing and personal risk stratiﬁcation could be designed consider-
ing the mutation spectrum present in the population.
The polygenic risk model for BC suggests that the effects
associated with genetic variants combine multiplicatively so
that the variants retain their nominal risk effects in the combi-
nations.37 This has been validated for common low-penetrance
variants and for common variants in combination with rare
mutations.38–40 However, as indicated by Sokolenko et al.,41
only few studies have been published on BC patients heterozy-
gous for high- and moderate-risk mutations. In the HelsinkiTa
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BC series, 0.4% of unselected and 0.6% of BRCA1/2-negative
familial patients carried a moderate-risk mutation in more
than one gene. The frequency of the double heterozygotes was
ﬁve times higher in the unselected BC cases (p = 0.149) and
over seven times higher in the familial BC cases (p = 0.030)
than in the population controls. The studied moderate-risk
mutations were detected also in 9.2% of the BRCA1/2-positive
index patients, more than twice as often as in the population
controls (p = 0.011; Table 5) and in 14.7% of the BRCA1/2
families. These ﬁndings comply with the multiplicative risk
model, where the second mutation confers additional risk. If it
did not, the mutation frequencies would be approximately the
same in the carrier patients as in the population controls.
However, the exact risk associated with any speciﬁc mutation
combination remains to be evaluated in larger patient groups.
Earlier studies have indicated that CHEK2 or ATM mutations
do not cause additional risk of BC in BRCA1/2-positive
patients.42,43 Here, FANCM variants appeared as the most
common second mutations with 5.5% frequency in the
BRCA1/2 index cases. However, even when excluding FANCM
mutations from the double heterozygote analyses, the ORs
were similar, even though statistically less signiﬁcant
(Supporting Information Table S5). It is also important to
notice that in the BRCA1/2 families, the moderate-risk gene
mutation was not always observed in the proband, but in
another BRCA1/2 carrier in the family.
Even though we pooled the mutations for the double het-
erozygote analyses, we appreciate that the moderate-
penetrance genes have different risk effects and that these
effects can be subtype-speciﬁc. CHEK2 mutations predispose
especially to ER-positive disease11 and are, like ATM muta-
tions, associated with approximately two- to threefold
increased risk of BC.9–13 However, for patients with a family
history of the disease, the risk estimates are often further
increased, which is likely due to other risk-increasing variants
in the families. The estimated lifetime risk of BC for CHEK2
mutation carriers ranges from about 20% for women without
affected relatives to up to approximately 40% for women with
positive family history.9–11 PALB2 mutations are associated
with about sixfold increased risk, and the estimated cumula-
tive risk of BC caused by PALB2 mutations is 35% by the age
of 70 years, but even 58% for carriers with a strong family
Table 4. Frequencies of the moderate-risk mutations in the BRCA1/2 index patients and families
Mutation1
BRCA1 index
patients (%),
n = 56
BRCA1
families (%),
n = 56
BRCA2 index
patients (%),
n = 53
BRCA2
families (%),
n = 53
BRCA1/2 index
patients (%),
n = 109
BRCA1/2
families (%),
n = 109
All BRCA1/2
patients2 (%),
n = 206
Healthy
BRCA1/2
carriers (%),
n = 55
ATM c.6908dupA 2 (3.6) 2 (3.6) 0 0 2 (1.8) 2 (1.8) 3 (1.5) 3 (5.5)
ATM c.7570G>C 0 0 0 1 (1.9) 0 1 (0.9) 1 (0.5) 0
CHEK2 c.1100delC 0 1 (1.8) 1 (1.9) 3 (5.7) 1 (0.9) 4 (3.7) 4 (1.9) 2 (3.6)
FANCM c.5101C>T 1 (1.8) 3 (5.4) 3 (5.7) 3 (5.7) 4 (3.7) 6 (5.5) 7 (3.4) 2 (3.6)
FANCM c.5791C>T 1 (1.8) 1 (1.8) 1 (1.9) 1 (1.9) 2 (1.8) 2 (1.8) 2 (1.0) 0
PALB2 c.1592delT 0 0 2 (3.8) 2 (3.8) 2 (1.8) 2 (1.8) 2 (1.0) 0
RAD51C c.93delG 1 (1.8) 1 (1.8) 0 0 1 (0.9) 1 (0.9) 1 (0.5) 0
Total3 4 (7.1) 7 (12.5) 6 (11.3) 9 (17.0) 10 (9.2) 16 (14.7) 18 (8.7) 7 (12.7)
1Only the mutations detected in the BRCA1/2 families are presented in the table.
2BRCA1/2 carriers including the index cases and family members with any cancer type.
3Triple heterozygotes are included only once in the total carrier frequencies.
Table 5. Frequencies of the second moderate-risk mutation in the carriers of BRCA1/2 or moderate-penetrance mutation
Second mutation
Group Carriers/total % OR1 95% CI p-value
Moderate-risk mutation carrier2 8/1293 6.2 1.72 0.69–3.79 0.155
BRCA1 index patient 4/56 7.1 2.01 0.51–5.80 0.164
BRCA2 index patient 6/53 11.3 3.32 1.11–8.34 0.016
BRCA1/2 index patient 10/109 9.2 2.63 1.15–5.48 0.011
Moderate-risk mutation
carrier2 or BRCA1/2 index patient
17/2373,4 7.2 2.01 1.06–3.65 0.021
1The frequency of a second mutation in the mutation carrier groups was compared to the overall frequency of moderate-risk mutations in the Helsinki
population controls (47/1273, 3.7%).
2In the Helsinki unselected breast cancer series.
3Includes one CHEK2 c.1100delC homozygote and one BRCA2 c.7480C>T, CHEK2 c.1100delC and FANCM c.5101C>T triple heterozygote.
4One BRCA2 index patient included also in the Helsinki unselected breast cancer series is counted only once in the total frequencies.
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history of the disease.8 RAD51C and RAD51D have recently
been suggested as risk genes for triple-negative BC,19 while
their contribution to OC with a ﬁve- to sixfold increased risk
has been acknowledged longer.16–18 We have previously iden-
tiﬁed FANCM as a BC predisposing gene in the Finnish popu-
lation with approximately twofold increased risk of BC.14,15
The highest risk was seen in the patients with the triple-
negative subtype. Similar results have been published in other
studies.44,45 FANCM has also been suggested as an OC suscep-
tibility gene.46 Here, 3.1% of the unselected OC patients car-
ried any of the three FANCM mutations.
We report a novel association between CHEK2 c.319
+2T>A and BC risk. This mutation, located at a canonical
splice site, was previously observed in a gene panel sequencing
of BC patients from Finland30 and in a Norwegian patient
with Cowden-like syndrome, thyroid cancer and bilateral
BC.47 We identiﬁed c.319+2T>A in 0.7% of BC patients in the
combined Helsinki and Tampere series. The mutation was
associated with a 5.4-fold risk of BC in the unselected patient
group, higher than the previous estimates for CHEK2 muta-
tions. The risk associated with c.319+2T>A here may be an
overestimate and the true risk closer to the approximately
threefold risk associated with the truncating CHEK2 muta-
tions.9,10,13 However, our estimate of sixfold increased risk in
the familial patient group is in line with the earlier studies on
CHEK2.9,10 We have previously detected the Eastern
European founder mutation CHEK2 c.444+1G>A in a gene
panel sequencing of Finnish BC and OC patients.29 As the
c.444+1G>A mutation was rare (0.1%) in our BC series, we
were not able to conﬁrm the associated risk in this study.
The carrier frequencies of ATM c.6908dupA and c.7570G>C
have previously been estimated in a Northern Finnish study.26
Here, we genotyped these rare ATM mutations in a large
series of 3,156 BC patients and 2,089 population controls to
establish the carrier frequencies in Southern Finland. ATM
c.6908dupA was detected in 0.8% of unselected BC patients
from the Tampere region, but only in 0.2% of familial and
0.1% of unselected cases from the Helsinki region. ATM
c.7570G>C was identiﬁed in 0.3% of familial and 0.1% of
unselected BC patients in the Helsinki series, but absent in
the Tampere patients. In a study by Pylkäs et al.,26 a haplo-
type analysis suggested both c.6908dupA and c.7570G>C to
be unique founder mutations, the former originating from
the Tampere region. The frequency of these pathogenic ATM
mutations was about two- to threefold higher in cases in
comparison to the population controls, which is consistent
with previous results on ATM.13,48 As the c.6908dupA and
c.7570G>C mutations are rare, a family-based penetrance
study might be better suited to estimate the risk effect associ-
ated with these mutations.
Genetic testing allows personalized risk assessment and can
lead to disease-preventive actions. An improved diagnostic yield
can be achieved with gene panels compared to single gene-based
tests. In our study, moderate-penetrance mutations were identi-
ﬁed with a relatively high overall frequency in the patients and
the results support the utilization of gene panels in clinical test-
ing, possibly for more than one individual in the family. Several
pathogenic variants may segregate also in a BRCA-positive fam-
ily and thus, the family members testing negative for BRCA1/2
mutations may remain at an increased risk of BC or OC due to
other predisposing mutations. Furthermore, Manchanda et al.49
estimated that, in UK and USA, population-based testing of
BRCA1/2 and moderate-risk genes would be more cost-effective
than testing by clinical or family history-based criteria. In a
founder population, like the Finns, screening the few recurrent
risk mutations could give similar cost-beneﬁts.
In conclusion, our study provides overall frequencies for
recurrent moderate-risk gene mutations in BC and OC
patients in Southern Finland. The frequency of the moderate-
penetrance gene mutations was signiﬁcantly different from the
frequency in the population controls also in the BRCA1/2
index patients and our data support the multiplicative risk
model, with the second mutation conferring additional
increase in risk. Our results underline the beneﬁts of gene
panel testing, possibly for multiple members of BC families
where several pathogenic variants may segregate in different
individuals.
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